Correct Answer: D. Proton
The Bragg peak is the phenomenon where charged particles (particularly protons) deposit maximum ionization energy at a specific depth in tissue, with minimal energy loss before and after that point. This is the defining characteristic of proton therapy and is most pronounced in protons because of their mass and charge properties. Protons are heavy enough to maintain a relatively straight trajectory through tissue (unlike electrons which scatter widely), yet light enough to be decelerated predictably by the Coulomb force. As a proton slows down approaching the end of its range, its ionization cross-section increases dramatically, creating the sharp Bragg peak. This peak can be positioned precisely at the tumor depth, delivering maximum dose to the target while sparing downstream normal tissues—a major advantage in Indian cancer centers adopting proton therapy (e.g., AIIMS Delhi, Fortis). The peak is sharp and well-defined because proton stopping power follows the Bethe-Bloch formula, with a characteristic rise near the end of range. In contrast, X-rays and neutrons do not exhibit this phenomenon, and electrons produce a much broader, less pronounced peak due to their small mass and high scattering.
Why the other options are wrong
A. X-ray — X-rays are photons (uncharged) and do not interact via Coulomb force. They deposit dose exponentially with depth following an attenuation curve, not a sharp peak. There is no Bragg peak phenomenon in X-rays; dose is maximum at the surface and decreases with depth. This is the fundamental difference between photon and particle therapy. B. Neutron — Neutrons are uncharged particles and do not experience Coulomb interactions with atomic electrons. They interact primarily via nuclear collisions, producing a broad dose distribution without a sharp peak. While neutrons can produce secondary charged particles, the Bragg peak effect is not characteristic of neutron beams and is not clinically exploited in neutron therapy. C. Electron — Electrons are charged but have very small mass, causing them to scatter extensively in tissue via multiple Coulomb interactions. This produces a broad, diffuse dose distribution with a much less pronounced peak compared to protons. Electron therapy is used clinically but does not exploit a sharp Bragg peak; instead, it relies on surface and shallow-depth dose delivery.
High-Yield Facts
- Bragg peak is the sharp rise in ionization energy deposition near the end of a charged particle's range in tissue.
- Proton therapy exploits the Bragg peak to deliver maximum dose to tumor while minimizing exit dose, reducing late toxicity in Indian cancer patients.
- Stopping power of protons increases as velocity decreases (inverse relationship with kinetic energy), creating the characteristic peak near range end.
- Proton range in tissue is predictable and depends on initial energy, allowing precise depth targeting without scatter.
- Electron beams produce a broader, less pronounced peak due to small mass and high scattering; not suitable for deep tumors.
- Photon (X-ray) dose follows exponential attenuation with depth; no Bragg peak phenomenon exists.
Mnemonics
BRAGG = Charged particles, Heavy, Range-defined, Gradient sharp Bragg peak occurs only with charged particles (protons, heavy ions). The peak is sharp because the particle has a defined range and deposits energy via Coulomb force. Use this when distinguishing particle therapy from photon/neutron therapy. PROTON > ELECTRON for Bragg Peak Protons are heavier and scatter less than electrons, producing a sharp, well-defined Bragg peak. Electrons scatter widely and produce a broad, diffuse dose distribution. Remember: mass matters for peak sharpness.
NBE Trap
NBE may pair "Bragg peak" with X-rays or electrons to test whether students confuse particle therapy with photon/electron therapy. The trap is assuming any high-energy radiation produces a Bragg peak; only charged particles with sufficient mass (protons, heavy ions) exhibit this phenomenon clinically.
Clinical Pearl
In Indian cancer centers, proton therapy is increasingly used for pediatric tumors (medulloblastoma, retinoblastoma) and head-neck cancers to exploit the Bragg peak and reduce secondary malignancy risk—a critical concern in young patients with decades of life ahead. The sharp dose falloff beyond the tumor is a game-changer in sparing adjacent organs like the heart in breast cancer or the contralateral parotid in nasopharyngeal cancer.
_Reference: Robbins & Cotran Pathologic Basis of Disease (Radiation Injury chapter); Harrison's Principles of Internal Medicine Ch. 100 (Cancer Therapy); Indian Radiotherapy Guidelines (ICMR/NCCN adapted for India)_